danielraymond's hcv [42 articles] Export

Recent papers added to danielraymond's library classified by the tag hcv. You can also see everyone's hcv.

	Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. [My Copy] Int J Epidemiol, Vol. 34, No. 1. (February 2005), pp. 121-130. by C. Lewden, D. Salmon, P. Morlat, et al.S. Bévilacqua, E. Jougla, F. Bonnet, L. Héripret, D. Costagliola, T. May, G. Chêne, posted to haart hcv hiv mortality by danielraymond on 2006-09-21 19:03:26 as along with 1 person markpoliz
	Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. [My Copy] Epidemiol Infect (17 May 2006), pp. 1-7. by J Amin, M G G. Law, J Micallef, et al.M Jauncey, I VAN Beek, J M M. Kaldor, G J J. Dore posted to acute clearance hcv idu by danielraymond on 2006-09-21 18:56:32 as
	Duration of peginterferon therapy in acute hepatitis C: a randomized trial. [My Copy] Hepatology, Vol. 43, No. 5. (May 2006), pp. 923-931. by S. M. Kamal, K. N. Moustafa, J. Chen, et al.J. Fehr, A. Abdel Moneim, K. E. Khalifa, L. A. El Gohary, A. H. Ramy, M. A. Madwar, J. Rasenack, N. H. Afdhal posted to acute duration hcv treatment by danielraymond on 2006-06-23 18:00:14 as
	Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. [My Copy] Gastroenterology, Vol. 130, No. 3. (March 2006), pp. 632-638. by S. M. Kamal, A. E. Fouly, R. R. Kamel, et al.B. Hockenjos, A. Al Tawil, K. E. Khalifa, Q. He, M. J. Koziel, K. M. El Naggar, J. Rasenack, N. H. Afdhal posted to acute hcv onset treatment by danielraymond on 2006-06-23 17:59:35 as
	VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. [My Copy] Antimicrob Agents Chemother, Vol. 50, No. 5. (May 2006), pp. 1813-1822. by K. Lin, R. B. Perni, A. D. Kwong, C. Lin posted to hcv protease-inhibitor vx-950 by danielraymond on 2006-06-23 17:58:22 as along with 1 person mccownm
	Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. [My Copy] Antimicrob Agents Chemother, Vol. 50, No. 3. (March 2006), pp. 899-909. by R. B. Perni, S. J. Almquist, R. A. Byrn, et al.G. Chandorkar, P. R. Chaturvedi, L. F. Courtney, C. J. Decker, K. Dinehart, C. A. Gates, S. L. Harbeson, A. Heiser, G. Kalkeri, E. Kolaczkowski, K. Lin, Y. P. Luong, B. G. Rao, W. P. Taylor, J. A. Thomson, R. D. Tung, Y. Wei, A. D. Kwong, C. Lin posted to hcv protease-inhibitor vx-950 by danielraymond on 2006-06-23 17:57:45 as along with 1 person josealonsoneto
	Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. [My Copy] Antiviral Res, Vol. 70, No. 2. (June 2006), pp. 28-38. by X. Tong, R. Chase, A. Skelton, T. Chen, J. Wright-Minogue, B. A. Malcolm posted to hcv protease-inhibitor resistance sch-503034 by danielraymond on 2006-06-23 17:56:56 as
	Intrahepatic Hepatitis C Virus Replication Correlates with Chronic Hepatitis C Disease Severity In Vivo [My Copy] J. Virol., Vol. 80, No. 5. (1 March 2006), pp. 2280-2290. by Sampa Pal, Margaret C. Shuhart, Lisa Thomassen, et al.Scott S. Emerson, Tao Su, Nathan Feuerborn, John Kae, David R. Gretch posted to hcv hiv intrehepatic replication by danielraymond on 2006-02-11 19:45:53 as
	Relation between viral fitness and immune escape within the hepatitis C virus protease. [My Copy] Gut, Vol. 55, No. 2. (February 2006), pp. 266-274. by J. Söderholm, G. Ahlén, A. Kaul, et al.L. Frelin, M. Alheim, C. Barnfield, P. Liljeström, O. Weiland, D. R. Milich, R. Bartenschlager, M. Sällberg posted to cd8 epitopes escape fitness hcv by danielraymond on 2006-01-29 19:02:02 as
	Do antiviral CD8+ T cells select hepatitis C virus escape mutants? Analysis in diverse epitopes targeted by human intrahepatic CD8+ T lymphocytes [My Copy] Journal of Viral Hepatitis, Vol. 13, No. 2. (February 2006), pp. 121-130. by H. Komatsu, G. Lauer, O. G. Pybus, et al.K. Ouchi, D. Wong, S. Ward, B. Walker, P. Klenerman posted to cd8 epitopes escape hcv by danielraymond on 2006-01-29 18:45:11 as
	Ethnic differences in the presentation of chronic hepatitis C [My Copy] Journal of Viral Hepatitis, Vol. 13, No. 2. (February 2006), pp. 116-120. by R. Lepe, J. E. Layden-Almer, T. J. Layden, S. Cotler posted to hcv latino by danielraymond on 2006-01-29 18:42:27 as
	Hepatitis C and steatosis: a reappraisal [My Copy] Journal of Viral Hepatitis, Vol. 13, No. 2. (February 2006), pp. 73-80. by A. Lonardo, P. Loria, L. E. Adinolfi, N. Carulli, G. Ruggiero posted to hcv steatosis by danielraymond on 2006-01-29 17:58:15 as
	Accumulation of dysfunctional effector CD8+T cells in the liver of patients with chronic HCV infection. [My Copy] J Hepatol (5 December 2005) by Carla Nisii, Massimo Tempestilli, Chiara Agrati, et al.Fabrizio Poccia, Guido Tocci, Maria Antonella A. Longo, Gianpiero D'Offizi, Roberto Tersigni, Oreste Lo L. Iacono, Giorgio Antonucci, Alessandra Oliva posted to cd8 dysfunction hcv by danielraymond on 2006-01-29 17:47:29 as
	Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). [My Copy] J Hepatol (20 December 2005) by Marianne Maynard, Pierre Pradat, François Bailly, et al.Frédéric Rozier, Chantal Nemoz, Si Nafa Si N. Ahmed, Patrice Adeleine, Christian Trepo, And A French Multicenter Group posted to amantadine hcv non-responder by danielraymond on 2006-01-29 17:45:35 as
	Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. [My Copy] Hepatology, Vol. 43, No. 1. (January 2006), pp. 100-107. by G. Raimondo, M. R. Brunetto, P. Pontisso, et al.A. Smedile, A. M. Maina, C. Saitta, G. Squadrito, N. Tono, posted to coinfection hbv hcv hdv by danielraymond on 2006-01-29 17:34:51 as
	Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis [My Copy] Journal of Viral Hepatitis, Vol. 12, No. 6. (November 2005), pp. 655-662. by A. Judd, S. Hutchinson, S. Wadd, et al.M. Hickman, A. Taylor, S. Jones, J. V. Parry, S. Cameron, T. Rhodes, S. Ahmed, S. Bird, R. Fox, A. Renton, G. V. Stimson, D. Goldberg posted to hcv idu prevalence risk by danielraymond on 2005-11-08 13:58:11 as along with 1 person norahpalmateer
	Viral evolution of hepatitis C in injection drug users [My Copy] Journal of Viral Hepatitis, Vol. 12, No. 6. (November 2005), pp. 574-583. by L. Dove, Y. Phung, N. Bzowej, M. Kim, A. Monto, T. L. Wright posted to hcv idu quasispecies reinfection by danielraymond on 2005-11-08 13:54:41 as
	Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection. [My Copy] AIDS Res Hum Retroviruses, Vol. 21, No. 9. (September 2005), pp. 743-752. by A. Mocroft, A. N. Phillips, V. Soriano, et al.J. Rockstroh, A. Blaxhult, C. Katlama, A. Boron-Kaczmarska, L. Viksna, O. Kirk, J. D. Lundgren posted to discontinuation haart hcv hiv toxicity by danielraymond on 2005-10-18 12:10:01 as
	Intrahepatic CD8(+) T-cell failure during chronic hepatitis C virus infection. [My Copy] Hepatology, Vol. 42, No. 4. (October 2005), pp. 828-837. by H. C. Spangenberg, S. Viazov, N. Kersting, et al.C. Neumann-Haefelin, D. McKinney, M. Roggendorf, F. von Weizsäcker, H. E. Blum, R. Thimme posted to cd8 chronic hcv intrahepatic by danielraymond on 2005-09-27 14:12:40 as
	Historical trends in the production and consumption of illicit drugs in Mexico: Implications for the prevention of blood borne infections. [My Copy] Drug Alcohol Depend, Vol. 79, No. 3. (1 September 2005), pp. 281-293. by J. Bucardo, K. C. Brouwer, C. Magis-Rodríguez, et al.R. Ramos, M. Fraga, S. G. Perez, T. L. Patterson, S. A. Strathdee posted to drugs hcv hiv idu mexico by danielraymond on 2005-09-04 17:46:11 as
	More Severe Parenchymal Injury in Chronic Hepatitis C Acquired by Recent Injection Drug Use. [My Copy] J Clin Gastroenterol, Vol. 39, No. 8. (September 2005), pp. 722-727. by Matthew M. Yeh, Zelma J. Buskell, Leonard B. Seeff, Doris Strader, Elizabeth C. Wright, Zachary D. Goodman posted to fibrosis hcv idu by danielraymond on 2005-09-04 16:50:46 as
	Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. [My Copy] Clin Infect Dis, Vol. 40 Suppl 5 (15 April 2005) by S. A. Strathdee, M. Latka, J. Campbell, et al.P. T. O'Driscoll, E. T. Golub, F. Kapadia, R. A. Pollini, R. S. Garfein, D. L. Thomas, H. Hagan, posted to hcv health idu interferon treatment young by danielraymond on 2005-07-16 06:33:38 as
	Updating the infection risk reduction hierarchy: preventing transition into injection. [My Copy] J Urban Health, Vol. 81, No. 1. (March 2004), pp. 14-19. by D. Vlahov, C. M. Fuller, D. C. Ompad, S. Galea, D. C. Des Jarlais posted to hcv idu initiation risk by danielraymond on 2005-07-16 06:31:28 as
	Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. [My Copy] Epidemiology, Vol. 15, No. 5. (September 2004), pp. 543-549. by H. Hagan, H. Thiede, D. C. Des Jarlais posted to hcv idu risk seroconversion by danielraymond on 2005-07-16 06:29:03 as
	Prevalence of markers of hepatitis viruses A, B, C and of HIV in healthy individuals and patients of a Cambodian province. [My Copy] Southeast Asian J Trop Med Public Health, Vol. 24, No. 2. (June 1993), pp. 239-249. by E. G. Thüring, H. I. Joller-Jemelka, H. Sareth, U. Sokhan, C. Reth, P. Grob posted to cambodia hcv prevalence by danielraymond on 2005-07-16 06:27:49 as
	Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. [My Copy] J Hepatol, Vol. 43, No. 2. (August 2005), pp. 225-234. by M. Korf, D. Jarczak, C. Beger, M. P. Manns, M. Krüger posted to hcv hur psma7 replicon sirna by danielraymond on 2005-07-16 06:25:11 as
	Mitochondrial dysfunction in hepatitis C. [My Copy] J Clin Gastroenterol, Vol. 39, No. 4 Suppl 2. (April 2005) by M. Korenaga, M. Okuda, K. Otani, T. Wang, Y. Li, S. A. Weinman posted to hcv mitochondria by danielraymond on 2005-07-16 06:23:56 as
	Liver enzyme values in injection drug users with chronic hepatitis C. [My Copy] Dig Liver Dis (9 June 2005) by S H H. Mehta, D Netski, M S S. Sulkowski, S A A. Strathdee, D Vlahov, D L L. Thomas posted to alt hcv idu uln by danielraymond on 2005-07-16 06:12:10 as
	Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. [My Copy] Addiction, Vol. 99, No. 5. (May 2004), pp. 621-633. by T. Rhodes, M. Davis, A. Judd posted to hcv idu knowledge prevention qualitative risk sharing by danielraymond on 2005-07-16 06:05:06 as
	Preventing hepatitis C: 'common sense', 'the bug' and other perspectives from the risk narratives of people who inject drugs. [My Copy] Soc Sci Med, Vol. 59, No. 9. (November 2004), pp. 1807-1818. by M. Davis, T. Rhodes, A. Martin posted to hcv idu narrative prevention risk by danielraymond on 2005-07-16 06:03:32 as
	Seroprevalence of hepatitis C virus and associated risk behaviours: a population-based study in San Juan, Puerto Rico. [My Copy] Int J Epidemiol, Vol. 34, No. 3. (June 2005), pp. 593-599. by C. M. Pérez, E. Suárez, E. A. Torres, K. Román, V. Colón posted to hcv prevalence puertorico risk by danielraymond on 2005-07-16 05:21:28 as
	An Interplay between Hypervariable Region 1 of the Hepatitis C Virus E2 Glycoprotein, the Scavenger Receptor BI, and High-Density Lipoprotein Promotes both Enhancement of Infection and Protection against Neutralizing Antibodies. [My Copy] J Virol, Vol. 79, No. 13. (July 2005), pp. 8217-8229. by B. Bartosch, G. Verney, M. Dreux, et al.P. Donot, Y. Morice, F. Penin, J. M. Pawlotsky, D. Lavillette, F. L. Cosset posted to envelope hcv hcvpp hdl hvr1 sr-bi by danielraymond on 2005-06-20 13:25:31 as
	High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. [My Copy] Gastroenterology, Vol. 127, No. 3. (September 2004), pp. 924-936. by G. M. Lauer, E. Barnes, M. Lucas, et al.J. Timm, K. Ouchi, A. Y. Kim, C. L. Day, G. K. Robbins, D. R. Casson, M. Reiser, G. Dusheiko, T. M. Allen, R. T. Chung, B. D. Walker, P. Klenerman posted to acute cd8 chronic hcv hla by danielraymond on 2005-06-20 13:16:26 as along with 1 person ernestbrons
	Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. [My Copy] Hepatology, Vol. 42, No. 1. (16 June 2005), pp. 104-112. by Andrea L L. Cox, Timothy Mosbruger, Georg M M. Lauer, Drew Pardoll, David L L. Thomas, Stuart C C. Ray posted to acute cd8 epitopes hcv by danielraymond on 2005-06-20 13:10:55 as
	Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes. [My Copy] Antimicrob Agents Chemother, Vol. 49, No. 6. (June 2005), pp. 2164-2171. by J. Z. Wu, G. Larson, H. Walker, J. H. Shim, Z. Hong posted to anemia hcv ribavirin valeant viramidine by danielraymond on 2005-06-15 19:55:16 as
	Potential cellular receptors involved in hepatitis C virus entry into cells. [My Copy] Lipids Health Dis, Vol. 4, No. 1. (19 April 2005) by Daniel Favre, Beat Muellhaupt posted to cd81 entry exosome hcv ldl-r lipids sr-bi by danielraymond on 2005-06-01 14:46:53 as
	Pilot study of interferon gamma for chronic hepatitis C. [My Copy] J Hepatol (26 April 2005) by Alejandro Soza, Theo Heller, Marc Ghany, et al.Glen Lutchman, T Jake Liang, June Germain, Henry H H. Hsu, Yoon Park, Jay H H. Hoofnagle posted to actimmune hcv treatment by danielraymond on 2005-06-01 14:23:15 as
	Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. [My Copy] Addiction, Vol. 97, No. 10. (October 2002), pp. 1277-1287. by R. Heimer, S. Clair, L. E. Grau, R. N. Bluthenthal, P. A. Marshall, M. Singer posted to hcv hiv idu knowledge risk by danielraymond on 2005-05-31 23:07:17 as along with 1 person norahpalmateer
	Neighborhood differences in patterns of syringe access, use, and discard among injection drug users: implications for HIV outreach and prevention education. [My Copy] J Urban Health, Vol. 80, No. 3. (September 2003), pp. 438-454. by D. Buchanan, S. Shaw, W. Teng, P. Hiser, M. Singer posted to access hcv hiv idu local syringe by danielraymond on 2005-05-31 22:57:37 as
	Writing about risk: use of daily diaries in understanding drug-user risk behaviors. [My Copy] AIDS Behav, Vol. 8, No. 1. (March 2004), pp. 73-85. by T. J. Stopka, K. W. Springer, K. Khoshnood, S. Shaw, M. Singer posted to ethnography hcv hiv idu risk by danielraymond on 2005-05-31 22:56:44 as
	Replicative Homeostasis: A fundamental mechanism mediating selective viral replication and escape mutation. [My Copy] Virol J, Vol. 2, No. 1. (11 February 2005) by Richard Sallie posted to escape evolution fitness hcv hiv quasispecies replication by danielraymond on 2005-05-30 23:59:48 as along with 2 people biplabbose prometheusmax
	Injecting shared drugs: an observational study of the process of drug acquisition, preparation, and injection by Puerto Rican drug users. [My Copy] J Psychoactive Drugs, Vol. 37, No. 1. (March 2005), pp. 37-49. by H. A. Finlinson, H. M. Colón, M. S. López, R. R. Robles, J. G. Cant posted to hcv hiv idu prevention by danielraymond on 2005-05-30 20:24:56 as

Note: You may cite this page as: http://www.citeulike.org/user/danielraymond/tag/hcv

hcv	42
idu	36
hiv	32
risk	16
msm	7
acute	6
cd8	6
health	5
prevention	5
soc	5
ttm	5
epidemiology	4
sep	4
sex	4
syringe	4
treatment	4
alcohol	3
cocaine	3
drugs	3
epitopes	3
escape	3
haart	3
methamphetamine	3
moderation	3
pharmacy	3
prevalence	3
protease-inhibitor	3
seroconversion	3
social	3
chronic	2
er	2
fitness	2
foucault	2
genetics	2
interferon	2
knowledge	2
methadone	2
narrative	2
quasispecies	2
race	2
replication	2
sharing	2
sr-bi	2
theory	2
vx-950	2
access	1
actimmune	1
adherence	1
alt	1
amantadine	1
amphetamine	1
amsterdam	1
anemia	1
behavior	1
cambodia	1
cd81	1
cessation	1
chicago	1
clearance	1
clinical-trials	1
coinfection	1
community	1
controlled-drinking	1
cooker	1
crack	1
cultural	1
debi	1
discontinuation	1
disparities	1
duration	1
dysfunction	1
efficacy	1
entry	1
envelope	1
ethnography	1
evolution	1
exosome	1
expertise	1
fear	1
fibrosis	1
frequency	1
harm-reduction	1
hav	1
hbt	1
hbv	1
hcvpp	1
hdl	1
hdv	1
heroin	1
hhrp	1
hla	1
hospital	1
housing	1
hur	1
hvr1	1
impulsivity	1
income-inequality	1
inhaler	1
initiation	1
interventions	1
intrahepatic	1
intravention	1
intrehepatic	1
latino	1
ldl-r	1
legal	1
lipids	1
local	1
messages	1
mexico	1
mitochondria	1
mortality	1
networks	1
non-responder	1
onset	1
partner_notification	1
pbmc	1
policy	1
polydrug	1
power	1
psma7	1
puertorico	1
qualitative	1
raceethnicity	1
reinfection	1
relative-income	1
replicon	1
resistance	1
ribavirin	1
riskreduction	1
satx	1
sch-503034	1
self-regulation	1
ses	1
sexworker	1
sf	1
sirna	1
socialmarketing	1
std	1
steatosis	1
stigma	1
structural	1
therapeutic-misconception	1
toxicity	1
uln	1
vaccine	1
valeant	1
viramidine	1
young	1

danielraymond's hcv [42 articles] Export

danielraymond's tags